Show MeYes, kratom can cause psychosis, but it is uncommon and almost always occurs under identifiable conditions: very high doses, chronic daily use, withdrawal, or use combined with other stimulants or in people with a bipolar or psychotic-disorder history. The mitragynine content in kratom acts simultaneously on mu-opioid and serotonin receptors, a dual mechanism that explains both its stimulant and opioid-like effects. Published case reports describe hallucinations, delusions, and agitation, typically after doses above 10-15 grams of raw leaf powder per day or concentrated extracts. Most users never develop psychosis, and the absolute risk appears low, but it is not zero.
The dual-receptor mechanism behind kratom psychosis
Kratom (Mitragyna speciosa) contains more than 40 alkaloids. Two dominate: mitragynine and its more potent relative, 7-hydroxymitragynine. Mitragynine is a partial agonist at the mu-opioid receptor with low intrinsic activity, meaning it activates the receptor weakly compared with morphine. That weak activation explains the mild euphoria, analgesia, and dependence potential at ordinary doses.
The psychosis-relevant part of the mechanism is serotonergic. Mitragynine and several minor alkaloids bind to serotonin 5-HT2A and 5-HT1A receptors and inhibit serotonin reuptake. The 5-HT2A receptor is the same target engaged by classic psychedelics such as LSD and psilocybin. At low occupancy, this produces stimulation and mood elevation. At high and sustained occupancy, particularly with repeated dosing that produces tolerance and escalating intake, it can produce perceptual disturbances.
There is a second, less obvious pathway. Mitragynine is metabolized by CYP3A4 into 7-hydroxymitragynine, which is roughly 13 to 46 times more potent at the mu receptor. Heavy or frequent dosing shifts the metabolite ratio toward the more potent compound. This is one reason concentrated extracts and high-dose daily use diverge sharply from occasional leaf use.
In plain terms: kratom is not a single drug but a moving mixture, and the balance that produces a pleasant stimulant effect can tip toward a hallucinogenic effect when dose and frequency climb.
Quantified context: how often psychosis is reported
The evidence base for kratom psychosis consists almost entirely of case reports and small case series, not controlled trials. This limits certainty. What the reports show is a consistent profile.
A review of published kratom case literature through the mid-2020s identified fewer than 50 documented cases of psychosis or mania attributed to kratom, against a user population estimated in the millions in the United States alone. That makes documented psychosis a fraction of a fraction of 1 percent of users, though underreporting is likely substantial because many users do not disclose kratom use to clinicians.
Dose patterns in the case reports are informative. Most psychotic episodes were associated with daily intake above 10 to 15 grams of leaf powder, or with concentrated extracts where mitragynine content is 5 to 20 times higher per gram than raw leaf. A smaller share occurred during withdrawal rather than intoxication.
The controlled pharmacology literature offers a useful anchor. Mitragynine doses in animal models that produce behavioral disruption are typically several-fold higher than the doses producing analgesia. This suggests a genuine dose-dependent threshold for the serotonergic effects, consistent with the human case pattern.
Timeline: when psychotic symptoms emerge
The time course matters for recognition. Kratom psychosis does not follow a single pattern, but the case literature clusters into three windows.
| Timing relative to use | Typical presentation | Reported frequency in cases |
|---|---|---|
| 30-120 minutes after a high dose | Agitation, visual distortion, panic | Most common in acute cases |
| 2-7 days of escalating daily use | Hallucinations, paranoid ideation, insomnia | Moderate share of cases |
| 24-72 hours after stopping | Delirium, disorientation, tremor | Smaller but well documented |
| 1-4 weeks of sustained heavy use | Mania-like syndromes with grandiosity | Rare, mostly bipolar history |
| With concurrent stimulant use | Acute psychosis within hours | Depends on co-used substance |
The withdrawal window is the most easily missed. A user who stops a high-dose habit and presents with confusion and hallucinations three days later may be misdiagnosed, because clinicians do not associate kratom cessation with psychosis.
Variations and risk factors: who develops psychosis
Not everyone who uses kratom heavily develops psychosis. The cases share specific vulnerabilities.
A personal or family history of bipolar disorder or schizophrenia is the strongest signal. Several case reports describe first-episode mania in people with a known bipolar diathesis who used kratom daily for a few weeks. The serotonergic and stimulant effects can act as a pharmacological trigger in a vulnerable brain.
Concurrent stimulant use is the second major factor. Kratom is frequently combined with caffeine, amphetamines, or cocaine. The combination compounds dopaminergic and noradrenergic load and compresses the timeline to hours rather than weeks.
Poly-substance use more broadly raises risk. Case series report kratom psychosis most often in people also using alcohol, benzodiazepines, or other opioids, which complicates attribution.
Concentrated extracts and enhanced products carry disproportionate risk. A standard leaf dose of 3 to 6 grams contains roughly 5 to 15 mg of mitragynine. Some commercial extracts deliver 50 to 200 mg per serving, a 10- to 40-fold increase.
Age and sleep deprivation matter. Several cases involved adolescents or young adults, and severe sleep loss from kratom's stimulant effect appears to amplify perceptual disturbance.
Correcting misconceptions about kratom and psychosis
A common claim is that kratom psychosis is a myth invented by regulators. The case literature is thin but real, and the mechanism is biologically plausible. Dismissing it entirely is not supported.
The opposite error is equally common: treating kratom as a reliably psychotogenic drug. The absolute incidence is low, and most heavy users never develop psychosis. The risk is concentrated, not universal.
Another misconception is that only extracts cause psychosis. Plain leaf at high daily doses appears in a substantial share of cases, particularly the withdrawal-associated presentations.
A subtler error concerns attribution. Kratom is often adulterated or substituted. Products sold as kratom have been found to contain O-desmethyltramadol and other synthetic opioids. Some reported "kratom psychosis" may reflect adulterants rather than mitragynine. Per the US FDA, kratom is not approved for any medical use and product purity is unregulated, so attribution in any individual case remains uncertain.
Red flags that warrant urgent evaluation
These signs suggest a psychotic process rather than ordinary kratom effects and require prompt medical assessment.
- Hallucinations that persist more than a few hours after the last dose
- Paranoid beliefs that others are watching or harming the person
- Disorientation to time, place, or person
- Severe agitation with risk of self-harm or harm to others
- Fever, rigid muscles, or rapid heart rate suggesting serotonin toxicity
- Confusion appearing 24 to 72 hours after stopping heavy use
What to actually do: practical steps
If you use kratom and are concerned about psychiatric effects, several concrete actions reduce risk.
Track your daily gram intake and product type. Staying at or below roughly 5 grams of plain leaf per day, used intermittently rather than daily, keeps exposure well below the dose range in the case reports.
Avoid combining kratom with stimulants, alcohol, or benzodiazepines. The combination data show a compressed timeline and higher severity.
Disclose kratom use to any clinician evaluating psychiatric symptoms. Attribution depends on the clinician knowing what was taken. Bring the product label if possible.
If you have a personal or family history of bipolar disorder or psychosis, treat kratom as a higher-risk substance and discuss it with a clinician before use.
Do not stop a heavy daily habit abruptly without support. Tapering over one to two weeks reduces withdrawal-associated confusion risk.
Limitations of the evidence
The core limitation is that no prospective study has measured psychosis incidence in kratom users. Everything rests on case reports, which are subject to publication bias and attribution error. The dose thresholds cited here are drawn from case patterns rather than controlled dose-response data, so treat them as approximate. Adulteration means some cases may not involve mitragynine at all. The mechanism is plausible and partly demonstrated in receptor-binding studies, but the exact serotonergic contribution to psychosis in humans remains a hypothesis rather than an established finding.